PROCEPT BioRobotics Corporation Common Stock Earnings Recaps
Q1 2026
Apr 30, 2026
Shares climbed 4.4% following PROCEPT BioRobotics’ Q1 2026 results, as investors responded positively to accelerated margin recovery, record system pricing, and confirmation of the company’s full-year profitability and growth objectives.
Key takeaways
- Q1 2026 revenue reached $83.1 million, up 20% year-over-year, in line with management’s stated expectations despite modest procedural impact from commercial realignment.
- Gross margin improved sharply to 65%, up from 61% in Q4 2025, reaching the company’s full-year guidance three quarters early; management now expects further sequential margin gains throughout 2026.
- U.S. Hydros system average selling price hit an all-time high of ~$485,000 (14% increase vs. Q4 2025), while handpiece ASPs rose 5% quarter-over-quarter and 10% year-over-year.
- Company reiterates full-year system placement plans, with 49 U.S. Hydros systems sold in Q1 (including 2 replacements) and strong initial response to the AQUABEAM replacement program.
- International expansion advanced with 7 Hydros systems sold in the UK and continued pipeline growth; regulatory momentum included a major clinical guideline upgrade in Europe and FDA clearance of second-generation software.
Q3 2025
Nov 5, 2025
PROCEPT BioRobotics reported robust third quarter 2025 results, achieving $83.3 million in total revenue, a 43% year-over-year increase, driven by strong capital system sales. The company remains focused on enhancing procedure utilization and expanding market awareness for its innovative Aquablation therapy.
Key takeaways
- Total revenue reached $83.3 million, with U.S. sales contributing $73.9 million, showcasing solid growth amidst market scrutiny.
- 58 U.S. capital systems shipped in the quarter, indicating a stable pricing environment despite tightening capital budgets in large hospital systems.
- Organizational changes aimed at improving commercial execution, including expedited new account launches and a sharpened focus on international markets.
- Potential expansion into prostate cancer treatment, supported by the ongoing WATER IV clinical trial, highlights the long-term growth opportunities beyond BPH.
- Commitment to enhancing patient awareness and accelerating therapy adoption, leveraging new talent within leadership.